Premium
THERAPEUTIC HOTLINE: A rare vandetanib‐induced photo‐allergic drug eruption
Author(s) -
Fava Paolo,
Quaglino Pietro,
Fierro Maria Teresa,
Novelli Mauro,
Bernengo Maria Grazia
Publication year - 2010
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2010.01360.x
Subject(s) - vandetanib , medicine , tyrosine kinase inhibitor , tyrosine kinase , dermatology , epidermal growth factor receptor , drug , oncology , pharmacology , cancer research , cancer , receptor
Vandetanib is an inhibitor of the vascular endothelial growth factor receptor 2 tyrosine kinase and the epidermal growth factor receptor tyrosine kinase, recently used in the treatment of different tumors. We describe a case of a photo‐allergic reaction to vandetanib in an 80‐year‐old Caucasian woman affected by metastatic non‐small cell lung cancer. Phototoxic reactions to vandetanib have been rarely reported in the literature. Dermatologists should be aware of this cutaneous side effect of vandetanib treatment and affected patients should be counseled to use adequate sun protection.